Autores: Chamorro Julián G., Castagnino Jorge P., Musella Rosa M., Frías Ana, Aranda Federico M., de Larrañaga Gabriela F.
Introduction: Arylamine N-acetyltransferase-2 (NAT-2) is a key human enzyme in drug detoxification and elimination. Mutations in NAT-2 affect the activity of anti-tuberculosis drugs and result in three different phenotypes: rapid (RA), intermediate (IA) and slow acetylators (SA). Methodology: The allelic, genotypic and phenotypic frequencies of NAT-2 were studied in 185 patients from Buenos Aires by restriction fragment length polymorphism. Conclusion: A high prevalence of SA might have an impact on anti-TB drug-induced hepatotoxicity.
Palabras clave: NAT-2; polymorphism; tuberculosis; acetylator profile; prevalence.
2012-09-26 | 482 visitas | Evalua este artículo 0 valoraciones
Vol. 6 Núm.9. Septiembre 2012 Pags. 671-674 J Infect Developing Countries 2012; 6(9)